Prostate Cancer in Firemen: Early Diagnosis Because of Increased Diagnostic Pressure?

Prostate Cancer Clinical Trial

Official title:

Early Detection of Prostate Cancer in Firefighters - a Register-based Study of Prognostic Factors and Survival

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03896178
• Other study ID #: 2019/542
• Status: Completed
• Start date: February 1, 2020
• Est. completion date: February 2, 2020

Study information

• Verified date: February 2021
• Source: Oslo University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Firefighters, police, military personnel and pilots are all shown to have a higher incidence of prostate cancer than the general population. A possible explanation for this is that these four groups of employees need regular mandatory health-checkups. If these checkups increase the chances of having a PSA or DRE performed one could expect the workers in question to have a higher probability than the general population of being diagnosed with prostate cancer. If this is the case the four groups should have cancers that are lower grade and have better survival. The investigators wish to examine this by comparing the four groups with a control group made up of all other workers with regards to prognostic factors at the time of diagnosis and survival rates. This will be done by extracting data from the Cancer Registry of Norway, coupled with employment data from Statistics Norway. This study is also a part of a project on cancer in firefighters. If the prostate cancers in firefighters differ significantly from the other three specified groups, this could point to an exposure specific for firefighters, e.g. fire smoke, as an etiologic factor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 137536
• Est. completion date: February 2, 2020
• Est. primary completion date: February 2, 2020
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All cases of prostate cancer as registered by the Cancer Registry of Norway

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• None, observational study
None, observational study

Locations

Country	Name	City	State
Norway	Cancer Registry of Norway	Oslo

Sponsors (10)

Lead Sponsor	Collaborator
Oslo University Hospital	Cancer Registry of Norway, Extrastiftelsen, Fagforbundet, Gjensidige Foundation, Norwegian Cancer Society, Norwegian Confederation of Trade Unions, Norwegian Firefighters Fight Cancer, Norwegian Labour Inspection Authority, The National Institute of Occupational Health

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cause-specific mortality rate for prostate cancer		From January 1st 1960 until December 31st 2018
Secondary	TNM staging		January 1st 1960 until December 31st 2018
Secondary	Gleason score	Score based on microscopic appearance of prostate cancer tissue. Sum of two scores, each ranging from 1-5 (only whole numbers), meaning the final score ranges from 2-10. A higher score is associated with a more aggressive/less differentiated tumor. It is normal to group scores 2-6 together in >7. It is also normal to differentiate between 7 (4+3) (worse), and 7 (3+4) (better).	January 1st 1960 until December 31st 2018
Secondary	PSA at time of diagnosis		January 1st 1960 until December 31st 2018
Secondary	Functional status at time of diagnosis (WHO classification)		January 1st 1960 until December 31st 2018